Default company panoramic image

RealBio Technology Inc.

RealBio Technnology is a life science research tools company, commercialing a 3D tissue culture device, to model human tumors in vitro.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Kalamazoo, MI, USA
  • Currency USD
  • Founded May 2009
  • Employees 2
  • Website

Company Summary

RealBio® Technology Inc. is a life science research tools company, commercializing a patented 3D tissue culture technology, to enable researchers to model human tumors in a laboratory. Current preclinical models are not clinically predictive, with 72% of anti-cancer agents failing phase 2 clinical trials. The RealBio System will improve drug discovery in two ways: 1) reduce the number of animal models 2) reduce the number of clinical failures.


  • Default avatar
    Paul Neeb
    President and CEO

    Accomplished C-Level executive, with experience in fund raising, strategy development and new company formation. Solid experience creating strategies to launch disruptive technologies. Demonstrated success in enhancing shareholder value during times of tremendous ambiguity. Diverse experience across big pharma, service organizations and start-ups, which contributes to expert problem resolution across various situations.

  • Default avatar
    William Pfund
    VP Product Development

    Bill has more than 25 years of experience in the pharmaceutical and life science industry. During 18+ years at Pfizer, he was responsible for activities spanning the entire drug development continuum including development and validation of cell-based assays. More recently, Bill worked in a contract research organization where he served as Director of immunoassay and biomarker services and Director of Business Development. Bill holds a M.S. (Micr

  • Default avatar
    Dalia Cohen
    Chief Scientific Officer

    Dr. Cohen is a pharmaceutical industry expert at the intersection of drug discovery, personalized medicine and genomic technologies with 25+ years of experience. Most recently, Dalia served as the CSO at Asterand and Rosetta Genomics. During the four years at Rosetta, she led product development and the launch of three cancer diagnostics. Prior to Rosetta, she was employed at Novartis and Sandoz in several senior executive positions.


  • Default avatar
    Jansen, Valk, Thompson and Reahm

Previous Investors

  • Default avatar
    Blue Water Angels
    Default avatar
    Biosciences Research and Commercialization Center (BRCC)
    Default avatar
    Michigan Preseed Fund